The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells.
R. J. Brentjens
No relevant relationships to disclose
I. Riviere
No relevant relationships to disclose
J. Park
No relevant relationships to disclose
M. Davilla
No relevant relationships to disclose
X. Wang
No relevant relationships to disclose
R. Yeh
No relevant relationships to disclose
N. Lamanna
No relevant relationships to disclose
M. G. Frattini
No relevant relationships to disclose
M. Sadelain
No relevant relationships to disclose